> For the complete documentation index, see [llms.txt](https://www.brexatlas.org/llms.txt). Markdown versions of documentation pages are available by appending `.md` to page URLs; this page is available as [Markdown](https://www.brexatlas.org/phase_2_roadmap.md). # PHASE\_2\_ROADMAP ## The Purpose of Phase II Phase I of BREXAtlas focused on discovery. The goal was to identify recurring patterns, mechanisms, relationships, discoveries, and research gaps across the foundational literature of bioelectric oncology. The result was: * 44 foundational studies * 44 BRE encyclopedia entries * Discovery Atlas * Research Gap Atlas * Mechanism Index * Frequency Index * Knowledge Relationship Map * AskAtlasX knowledge framework Phase II begins where Phase I ends. The purpose of Phase II is not to collect more studies. The purpose of Phase II is to systematically validate, challenge, expand, and refine the discoveries identified in Volume I. *** ## What Phase II Is Not Phase II is not: * random paper collection * literature hoarding * simple expansion of the database * repeating Phase I Every future study must serve a specific purpose. Each study should contribute to: * a discovery * a research gap * a mechanism * a frequency relationship * a tissue expansion * a predictive model If a study does not contribute to one of these categories, it should not be prioritized. *** ## Phase II Mission Validate. Expand. Predict. Translate. *** ## Primary Goals ### Goal 1 ## Validate Discovery Atlas Findings The first objective is to determine whether the major discoveries identified in Volume I remain consistent across additional evidence. Priority discoveries include: * DISC-001 Frequency Sensitivity * DISC-003 DNA Repair Vulnerability * DISC-005 Calcium Signaling * DISC-007 Tumor Network Biology * DISC-008 Mitochondrial Vulnerability **Success Criteria:** Independent evidence repeatedly confirms the discovery across multiple tissues and cell lines. *** ### Goal 2 ## Close Research Gaps Phase II studies should be selected according to the Research Gap Atlas. Highest Priority Gaps: * RG-001 Frequency Specificity Validation * RG-005 Calcium Antenna Validation * RG-007 Tumor Network Validation * RG-008 Mitochondrial Vulnerability Validation * RG-010 Clinical Translation Scaling **Success Criteria:** Research gaps become smaller, clearer, or resolved. *** ### Goal 3 ## Expand Cell-Line Coverage Phase I established a foundation. Phase II should broaden coverage. Priority Areas: * Additional glioblastoma lines * Additional breast cancer lines * Additional liver cancer lines * Additional lung cancer lines * Ovarian cancer * Colon cancer * Prostate cancer * Leukemia * Head and Neck cancers * Melanoma expansion **Success Criteria:** Expanded tissue and cell-line representation. *** ### Goal 4 ## Expand Frequency Mapping Phase I suggests frequency matters. Phase II must determine: * optimal frequencies * frequency ranges * tissue specificity * signal architecture effects **Success Criteria:** Creation of a preliminary Frequency Specificity Atlas. *** ### Goal 5 ## Validate Calcium Signaling Models Phase I repeatedly identified calcium signaling. Phase II must determine: * which channels are involved * which tissues depend on them * whether calcium signaling predicts response **Success Criteria:** Validation or rejection of calcium-centered response models. *** ### Goal 6 ## Validate Tumor Network Biology Glioblastoma evidence suggests tumor communication networks may be therapeutic targets. Phase II should investigate: * tumor microtubes * communication networks * network synchronization * tumor adaptation **Success Criteria:** Network biology expands beyond glioblastoma. *** ### Goal 7 ## Validate Mitochondrial Vulnerability Cancer metabolism emerged repeatedly. Phase II should investigate: * mitochondrial respiration * metabolic stress * ROS generation * bioenergetic collapse **Success Criteria:** Cross-cancer confirmation of mitochondrial vulnerability. *** ### Goal 8 ## Expand Precision Nanobioelectric Oncology Phase I identified nanoparticle amplification as a promising field. Phase II should investigate: * ferroelectric nanoparticles * field amplification * delivery systems * targeting systems **Success Criteria:** Development of a Precision Nanobioelectric Oncology framework. *** ### Goal 9 ## Improve Predictive Modeling The long-term purpose of BREXAtlas is prediction. Future studies should strengthen: * AskAtlasX * ontology systems * response prediction * discovery prediction **Success Criteria:** Generation of preliminary predictive response models. *** ### Goal 10 ## Support Clinical Translation Ultimately discoveries must reach patients. Phase II should prioritize: * clinical TTFields evidence * clinical RF evidence * treatment combinations * implementation systems **Success Criteria:** Improved understanding of how discoveries become treatments. *** ## Recommended Study Selection Framework Every future paper should answer one or more of the following questions: **Discovery Validation** Which discovery does this study validate? **Research Gap Reduction** Which gap does this study help close? **Mechanism Expansion** Which mechanism does this study strengthen? **Frequency Expansion** Does this improve frequency mapping? **Tissue Expansion** Does this add a new tissue or cell line? **Translation Expansion** Does this improve clinical applicability? *** ## Expected Deliverables At the completion of Phase II, BREXAtlas should produce: * Volume II * Gap Resolution Studies * Expanded Discovery Atlas * Validated discoveries * Expanded Frequency Atlas * Cross-cancer frequency maps * Expanded Cell-Line Atlas * Additional tissue representation * Predictive Response Models * Initial prediction frameworks * Expanded AskAtlasX * Improved ontology and search capability *** ## Long-Term Vision Phase I created the map. Phase II tests the map. Phase III predicts the map. Phase IV translates the map. Phase V operationalizes the map. *** ## Phase II Success Definition Phase II will be considered successful if BREXAtlas can demonstrate: * stronger discovery confidence * reduced research uncertainty * expanded tissue coverage * expanded frequency coverage * improved ontology quality * improved predictive capability * improved clinical relevance The objective is not to build a larger database. The objective is to build a smarter one. *** ## Final Statement The next 44 studies should not be selected because they are available. They should be selected because they answer a question. Phase I identified those questions. Phase II exists to answer them. Every future upload should move BREXAtlas closer to a predictive, translational, and clinically relevant understanding of bioelectric oncology. --- # Agent Instructions This documentation is published with GitBook. GitBook is the documentation platform designed so that both humans and AI agents can read, navigate, and reason over technical content effectively. Learn more at gitbook.com. ## Querying This Documentation If you need additional information that is not directly available in this page, you can query the documentation dynamically by asking a question. Perform an HTTP GET request on the current page URL with the `ask` query parameter, and the optional `goal` query parameter: ``` GET https://www.brexatlas.org/phase_2_roadmap.md?ask=&goal= ``` `ask` is the immediate question: it should be specific, self-contained, and written in natural language. `goal` is optional and describes the broader end goal you are ultimately trying to accomplish on behalf of the user. GitBook uses it to tailor the answer towards what is most useful for that goal. The response will contain a direct answer to the question and relevant excerpts and sources from the documentation. Use this mechanism when the answer is not explicitly present in the current page, you need clarification or additional context, or you want to retrieve related documentation sections.